Trials / Completed
CompletedNCT01153321
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2423 | 100mg Oral dose od |
| DRUG | AZD2423 Placebo | Oral dose od |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-06-30
- Last updated
- 2015-04-10
- Results posted
- 2014-10-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01153321. Inclusion in this directory is not an endorsement.